Bluepharma Industria Farmaceutica SA (Bluepharma) is a pharmaceutical company that develops, manufactures and markets generic drugs. The company offers products for various therapeutic areas such as gastroenterology, cardiovascular system, central nervous system, urologicals and psycholeptics. Its products include acarbose, gliclazide, febuxostat, amlodipine, enalapril, irbesartan, losartan, ramiprill, fluoxetine, azithromycin, and others. Bluepharma’s services include licensing-out of developed dossiers, manufacturing by contract in a GMP environment, product development by contract or through partnership, and research and development services. The company markets its products through its distributors. BluePharma is headquartered in Coimbra, Portugal.
Bluepharma Industria Farmaceutica SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report by Diagnostic Test (Bone Marrow Examination, Complete Blood Count Test (CBC), Flow Cytometry, Lactate Dehydrogenase Test (LDH), and Urine Test for Hemosiderin), by Treatment (Blood Transfusion, Medication, and Stem Cell Transplant) - Global Forecast to 2025...
Pharmaceutical Bottles Market Research Report by Bottle (Dropper Bottles, Liquid Bottles, and Packer Bottles), by Application (Droppers, E-Liquid, Liquid, and Oral Care), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast across...
Clinical Trial Supply & Logistics for Pharmaceutical Industry Market Research Report by Sector (Clinical Trial Logistics and Distributions, Clinical Trial Manufacturing Services, and Clinical Trial Supply Chain Management) - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides...
206 pages •
By The Business Research Company
• Dec 2020
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market. Description: Where is the largest and fastest growing...
Seasonal Influenza Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Seasonal Influenza Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Seasonal Influenza Clinical trials scenario. This report provides top line data relating to the clinical...
Macular Edema Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Macular Edema Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Macular...
Peripheral Neuropathic Pain - Global Clinical Trials Review, H2 2020 Summary clinical trial report, “Peripheral Neuropathic Pain - Global Clinical Trials Review H2 2020" provides an overview of Peripheral Neuropathic Pain Clinical trials scenario. This report provides top line data relating to the...
The North America addictions therapeutics market is expected to reach US$ 6,102.31 million by 2027 from US$ 3,715.23 million in 2019. The market is estimated to grow with a CAGR of 6.5% from 2020 to 2027. The growth of the market is attributed to the rising approval of new drugs and launch of digital therapeutics to treat addiction, and...
The Europe cell line development serum market is expected to reach US$ 422.61 million in 2027 from US$ 268.68 million in 2019. The market is estimated to grow with a CAGR of 5.9% from 2020 to 2027. Increasing adoption of regenerative medicines, rising prevalence of cancer across the world, and increasing investments in R&D by pharmaceutical...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.